Autolus
Clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Learn more
Launch date
Employees
Market cap
$1.1b
Enterprise valuation
$430m (Public information from Sep 2024)
Share price
$3.85 AUTL
Company register number 09115837
London England (HQ)
Authorizing premium user...